Voyageur Mutual Funds has recently submitted its NPORT-P report, providing an update on the financial status of its Nomura Minnesota High-Yield Municipal Bond Fund. This report, filed on October 29, 2026, is crucial as it showcases the fund's performance and financial health in a competitive investment landscape.
The Nomura Minnesota High-Yield Municipal Bond Fund, part of Voyageur Mutual Funds, has reported total assets of approximately $246.9 million. The net assets of the fund are about $243 million, indicating a robust financial position. This filing is significant as it reflects the fund's ability to attract and manage investor capital effectively.
Background
Voyageur Mutual Funds, identified by the Central Index Key (CIK) 0000906236, operates as an investment entity. The firm focuses on managing mutual funds, particularly in the municipal bond sector. The latest filing is part of a series of NPORT-P submissions, with the most recent being on October 29, 2026. The firm has a history of providing investment options that cater to various investor needs.
What the Filing Says
The filing details key financial metrics for the Nomura Minnesota High-Yield Municipal Bond Fund. It states, "Total assets: $246,887,126.06; Net assets: $243,017,675.73." These figures highlight the fund's capacity to maintain a significant asset base while managing liabilities effectively.
Impact
This report may affect various stakeholders, including investors looking for stable returns in the municipal bond market. The filing highlights the fund's performance, which could influence investor decisions in a sector characterized by competition among firms managing similar investment products.
What's Next
The filing does not say what happens next. However, it is expected that Voyageur Mutual Funds will continue to monitor its fund performance and may release additional updates in future filings.
Read Next
Jefferies CEO Handler Reports Stock Transactions in SEC Filing
Brophy Michael Burkes sells 3,084 shares of Natera stock
Glenbrook Capital Management Boosts Stake in SenesTech
OS Therapies grants stock options to Chief Medical Officer
Belite Bio CEO Lin Yu-Hsin Vests 5,000 Shares
Chen Wan-Shan Reports Share Transaction for Belite Bio






